Impact of antiphospholipid antibodies on cardiac valve lesions in systemic lupus erythematosus: a systematic review and meta-analysis

• Published in: Clinical and experimental medicine Vol. 24; no. 1; p. 147
• Main Authors: Chen, Siyun, Zhou, Yangzhong, Wang, Chuhan, Jiang, Hui, Zhao, Yuan, Zhao, Jiuliang, Huang, Can, Li, Mengtao, Zhao, Yan
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 03.07.2024; Springer Nature B.V
• Subjects: Antibodies; Antibodies, Anticardiolipin - blood; Antibodies, Antiphospholipid - blood; Antiphospholipid antibodies; Aorta; Cardiolipin; Coronary artery disease; Glycoprotein I; Heart; Heart diseases; Heart Valve Diseases - immunology; Heart Valves - pathology; Hematology; Humans; Internal Medicine; Lung diseases; Lupus; Lupus Coagulation Inhibitor - blood; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - immunology; Medicine; Medicine & Public Health; Meta-analysis; Mitral valve; Oncology; Rheumatic heart disease; Sensitivity analysis; Systemic lupus erythematosus; Tricuspid valve; Heart valve disease; Systemic lupus erythematosus; Antiphospholipid antibodies; Meta-analysis

This meta-analysis assesses antiphospholipid antibodies’ (aPLs) impact on heart valve disease in Systemic Lupus Erythematosus (SLE) patients. We searched PubMed, Embase, Cochrane, and Web of Science up to January 2024 for comparative studies of heart valve disease in aPL-positive versus aPL-negative...